December 26, 2017 / 11:35 AM / 9 months ago

BRIEF-Soliris(Eculizumab) Gets Marketing Authorization In Japan For Treatment Of Patients With gMG

Dec 26 (Reuters) - Alexion Pharmaceuticals Inc:

* SOLIRIS® (ECULIZUMAB) RECEIVES MARKETING AUTHORIZATION IN JAPAN FOR THE TREATMENT OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below